At the ECCO 2019 European Cancer Summit in Brussels, it was a privilege to speak to Ruth Ladenstein, Project Coordinator, European Reference Network (ERN) for paediatric cancer (ERN PaedCan), to discuss the EU Cancer Mission and enabling cancer treatment across borders.
1. The European Commission has outlined a mission-oriented approach for the next Framework Programme for Research which will involve cancer as a topic. What is the purpose and scope of this mission? (0:10)
2. Is cancer care access and quality similar and continuous across European countries or is it variable with differing provision and standards depending on location? What are the causes of the differences? (1:43)
3. Is there a need to establish a quality standard of cancer care across European borders and is this becoming a reality? (3:20)
4. To what extent can healthcare professionals in different European states learn from practices elsewhere and adopt them for their own patients? (3:58)
5. In the future, is best practice in cancer likely to be increasingly uniform across Europe or is it likely to be unequal and dependent on healthcare funding or the patient’s ability to pay? (4:56)
Ruth Ladenstein has no conflicts of interest to declare in relation to this video.
Filmed in partnership with the European CanCer Organisation at the ECCO 2019 European Cancer Summit in Brussels, Belgium.
Share this Video
Related Videos In Policy
Raising awareness around HPV infection, cancer risk and vaccination: PrEvCan | Daniel Kelly
The PrEvCan – Cancer Prevention Across Europe – campaign, initiated by the European Oncology Nursing Society (EONS) and supported by ESMO, aims to reduce the burden of cancer by promoting a different way we can decrease cancer risk each month. This August, the PrEvCan campaign focuses on raising awareness about the connection between human papillomavirus […]
Vivek Subbiah, AACR 2023: The purpose of phase I clinical trials
The purpose of phase I clinical trials are to evaluate the safety, dosage and potential side effects of a new drug or treatment in humans for the first time. In this touchONCOLOGY interview, we speak with Dr Vivek Subbiah (University of Texas, MD Anderson Cancer Centre, Houston, TX, USA) to discuss the purpose and details […]
Vivek Subbiah, AACR 2023: The evolution of phase I clinical trials in the era of precision medicine
Precision medicine aims to tailor medical treatments to individual patients based on their characteristics and genetic makeup. Phase I clinical trials are seeing changes in their objectives and designs in the era of precision medicine. In this touchONCOLOGY interview, we speak with Dr Vivek Subbiah (University of Texas, MD Anderson Cancer Centre, Houston, TX, USA) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!